Home›Drug Pipeline› RNA-based approaches show potential as obesity biomarkers and therapeutic targets
RNA-based approaches show potential as obesity biomarkers and therapeutic targetsRNA molecules show promise for treating obesity and related diseases
Frontiers in MedicinePublished August 24, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider RNA-based approaches as promising but unvalidated; await further research on biomarkers and delivery.
This mini-review examines the role of RNA-based approaches, specifically microRNAs, long non-coding RNAs, circular RNAs, and tRNA-derived small RNAs, in obesity and associated conditions such as diabetes, cardiovascular disease, and fatty liver disease. The scope is broad, covering both diagnostic and therapeutic applications, but the evidence is largely at an exploratory stage.
The review highlights that profiles of many circulating miRNAs have been reported to differ between patients with obesity compared to healthy lean individuals, suggesting their potential as diagnostic biomarkers. Additionally, the authors discuss the potential for RNA-based approaches in disease risk assessment and as therapeutic targets in obesity, possibly through personalized anti-obesity therapies using multi-omics approaches.
However, the authors emphasize significant limitations, including the need for biomarker validation and the challenge of developing effective RNA delivery systems to target organs. These hurdles indicate that RNA-based diagnostics and therapies are not yet ready for clinical use.
Given the early-stage nature of the evidence, clinicians should interpret these findings cautiously. While the potential is intriguing, RNA-based approaches are not yet validated as clinical diagnostics or treatments, and further research is needed to overcome the identified barriers.
How this fits prior evidence
This mini-review extends prior coverage by exploring a novel molecular avenue for obesity and cardiometabolic risk. Unlike prior findings on environmental exposures (e.g., bisphenols and prothrombotic phenotypes) or specific interventions (e.g., PCSK9 inhibitors for MACE reduction), this review focuses on endogenous RNA molecules as potential biomarkers and therapeutic targets. It addresses a gap by proposing RNA-based diagnostics for obesity, complementing existing risk-stratification tools. However, the evidence is preliminary, and the authors note challenges in validation and delivery, contrasting with the more mature clinical data for PCSK9 inhibitors.
Living with obesity often comes with a host of complications, including type 2 diabetes, heart disease, and fatty liver disease. Doctors are looking for better ways to identify these risks early and find more effective ways to treat them.
Researchers have identified specific RNA molecules in the blood that change when a person is struggling with obesity compared to someone who is lean. These molecules, known as microRNAs or other types of RNA, could serve as biomarkers. A biomarker is a measurable sign that helps doctors understand a patient's health status more clearly.
While these RNA-based approaches show potential for personalized treatment and risk assessment, there are still hurdles to clear. Scientists must first validate these markers and find reliable ways to deliver the treatments directly to the right organs in the body. These tools are not yet ready for clinical use, but they offer a new path for future medicine.
What this means for you:
RNA molecules could eventually help doctors diagnose and treat obesity and related conditions like heart disease.
Common questions
What are these RNA-based approaches?
These are tools using different types of RNA, such as microRNAs and circular RNAs. They can act as biomarkers to help doctors see signs of illness or serve as targets for new treatments for conditions like obesity and fatty liver disease.
How do these molecules help with obesity?
Studies show that the levels of certain RNA molecules in the blood differ between people with obesity and lean individuals. This means they could eventually be used to assess risk or provide personalized therapies for those struggling with weight.
Are these treatments available now?
No, these RNA-based methods are not yet validated as clinical diagnostics or treatments. Researchers still need to solve problems with biomarker validation and finding effective ways to deliver the treatment to the correct organs.
Obesity is a global, complex, and multifactorial disease, and a major risk factor for diabetes, cardiovascular disease, fatty liver disease, and cancer. Despite its high prevalence, effective diagnostic and therapeutic strategies remain limited. Conventional anthropometric measurements, such as body mass index (BMI) and waist circumference, offer limited accuracy in assessing the impact of excess adiposity and related comorbidities on individual patients. Current anti-obesity pharmacotherapies also show inconsistent efficacy, are often associated with systemic side effects, and poor adherence to necessary lifestyle modifications, which limit their long-term success. Emerging evidence underscores the critical role of non-coding RNAs, including microRNAs, long non-coding RNAs, circular RNAs, and tRNA-derived small RNAs in key metabolic processes such as adipogenesis, insulin signalling, and appetite control. Notably, the profiles of many circulating miRNAs have been reported to differ between patients with obesity compared to healthy lean individuals, suggesting their potential as minimally invasive diagnostic biomarkers. In this mini-review, we discuss the clinical promise of RNA-based approaches for disease risk assessment and as therapeutic targets in obesity. In addition, we discuss key challenges, including biomarker validation and effective RNA delivery systems to the target organs. Multi-omics approaches may help overcome many of these limitations and enable the development of targeted and personalized RNA-based anti-obesity therapies.
